Two Rituxan Applications for CLL Indication Planned This Year

Genentech will seek approval to market its blockbuster anti-CD20 Rituxan drug to treat chronic lymphocytic leukemia (CLL), with a goal of submitting two sBLAs in the third quarter this year. The sBLAs will be based on data from the clinical trials CLL8 and REACH, which show that Rituxan (rituximab) combined with chemotherapy significantly increases progression-free survival in first- and second-line treatment settings.
Drug Industry Daily